A

Affimed NV
D

AFMD

1.00000
USD
-0.01
(-0.99%)
Market Closed
Volume
4
EPS
-3
Div Yield
-
P/E
-0
Market Cap
16,392,343
Related Instruments
    A
    ADAP
    -0.01800
    (-3.11%)
    0.56000 USD
    A
    ARVN
    -0.600
    (-3.27%)
    17.750 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    R
    RCKT
    -0.390
    (-3.59%)
    10.470 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    More
News

Title: Affimed NV

Sector: Healthcare
Industry: Biotechnology
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents anapproach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.